Tetraphase Pharmaceuticals Inc. (Nasdaq: TTPH) reported positive results from a Phase 3 clinical trial of eravacycline lifting the stock price 98 cents to close at $7.88.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|